down arrow

Mercury Labs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE947G01011
  • NSEID:
  • BSEID: 538964
INR
823.80
7.25 (0.89%)
BSENSE

Apr 11, 11:42 AM

BSE+NSE Vol: 1

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Mercury Laboratories Ltd stock-summary
stock-summary
Mercury Laboratories Ltd
Micro Cap
Pharmaceuticals & Drugs
Mercury Laboratories Limited, the registered partnership firm started its business activity in year 1962. Subsequently, the Company converted into Private Limited Company & incorporated in February, 1982. Later, it further converted into Limited Company in 1992 in Maharashtra. The Company is engaged in the business of Pharmaceutical items, medicinal drugs and formulations. It is a profit making and dividend paying public limited company.
Company Coordinates stock-summary
Company Details
1st Floor 18 Shreeji Bhuwan 51, Princess Street Mangaladas Rd Mumbai Maharashtra : 400002
stock-summary
Tel: 91-22-66372841
stock-summary
mllbrd@mwercurylabs.com
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
stock-summary Capital Structure
Capital Structure stock-summary
Present Equity Capital
INR 1.20 Cr
Number of Shares
12 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
Equity
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
31-Mar-2015
12
1.20
400
10
Unspecified
31-Mar-2015
12
1.20
400
10
Unspecified
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Shah Dilip Ramanlal Huf (25.88%)

Highest Public shareholder

Rajeshri K Shah (2.2%)

Individual Investors Holdings

16.63%

stock-summary Board of Directors
stock-summary
stock-summary
Management
Designation
Remuneration
Rajendra R Shah
ED / MD / Promoter
18.86 lacs
Dilip R Shah
Non Executive Director
29.0 k
Divyakant Ramniklal Zaveri
Chairman & Independent Directo
44.0 k
Bharat Dhirajlal Mehta
Independent Non Exe. Director
44.0 k
Paresh Mistry
Non-Exec & Non-Independent Dir
35.0 k
Janki Shah
Non Executive Director
24.0 k
stock-recommendationRaw Materials
Raw Materials Dashboard stock-summary
Raw Materials
Amount(Rs Cr)
% of RM Cost
Trimethoprim IP
0.99063
0%
 
100
Trimethoprim IP
stock-recommendation Finished Goods
Finished Goods Dashboard stock-summary
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Others
37.53
71.62%
Paracetamol Tab
4.85
9.26%
Gravidol Tablet
3.94
7.52%
 
71.62
Others
28.38
Others
9.26
Paracetamol Tab
90.74
Paracetamol Tab
7.52
Gravidol Tablet
92.48
Gravidol Tablet
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
20 Cr
(Quarterly Results - Dec 2024)
Net Profit:
1 Cr
stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 98 Cr (Micro Cap)

stock-summary
P/E

25.00

stock-summary
Industry P/E

27

stock-summary
Dividend Yield

0.43%

stock-summary
Debt Equity

0.04

stock-summary
Return on Equity

7.62%

stock-summary
Price to Book

1.90